Literature DB >> 2935937

Atrial natriuretic peptide elevation in congestive heart failure in the human.

J C Burnett, P C Kao, D C Hu, D W Heser, D Heublein, J P Granger, T J Opgenorth, G S Reeder.   

Abstract

A sensitive radioimmunoassay for atrial natriuretic peptide was used to examine the relation between circulating atrial natriuretic peptide and cardiac filling pressure in normal human subjects, in patients with cardiovascular disease and normal cardiac filling pressure, and in patients with cardiovascular disease and elevated cardiac filling pressure with and without congestive heart failure. The present studies establish a normal range for atrial natriuretic peptide in normal human subjects. These studies also establish that elevated cardiac filling pressure is associated with increased circulating concentrations of atrial natriuretic peptide and that congestive heart failure is not characterized by a deficiency in atrial natriuretic peptide, but with its elevation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2935937     DOI: 10.1126/science.2935937

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  154 in total

Review 1.  Natriuretic peptide receptor: structure and signaling.

Authors:  Kunio S Misono
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

Review 2.  Novel natriuretic peptides: new compounds and new approaches.

Authors:  Mark W Vogel; Horng H Chen
Journal:  Curr Heart Fail Rep       Date:  2011-03

3.  Integrated cardiac, renal, and endocrine actions of endothelin.

Authors:  W L Miller; M M Redfield; J C Burnett
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

Review 4.  Atrial natriuretic factor: a hormone secreted by the heart.

Authors:  D D Macchia
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

5.  A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome.

Authors:  Masao Murakami; Masayo Nakagawa; Eric N Olson; Osamu Nakagawa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-06       Impact factor: 11.205

6.  A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension.

Authors:  Paul M McKie; Alessandro Cataliotti; Guido Boerrigter; Horng H Chen; S Jeson Sangaralingham; Fernando L Martin; Tomoko Ichiki; John C Burnett
Journal:  Hypertension       Date:  2010-10-25       Impact factor: 10.190

Review 7.  Neurohormonal mechanisms and the role of angiotensin-converting enzyme (ACE) inhibitors in heart failure.

Authors:  A J Coats; S Adamopoulos
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

8.  C-type natriuretic peptide levels in cor pulmonale and in congestive heart failure.

Authors:  R I Cargill; C S Barr; W J Coutie; A D Struthers; B J Lipworth
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

9.  Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.

Authors:  M Mukoyama; K Nakao; K Hosoda; S Suga; Y Saito; Y Ogawa; G Shirakami; M Jougasaki; K Obata; H Yasue
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

10.  Low-dose dasatinib rescues cardiac function in Noonan syndrome.

Authors:  Jae-Sung Yi; Yan Huang; Andrea T Kwaczala; Ivana Y Kuo; Barbara E Ehrlich; Stuart G Campbell; Frank J Giordano; Anton M Bennett
Journal:  JCI Insight       Date:  2016-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.